Sinogen Pharmaceutical announced that the oncolytic bacterial product SalMet-Vec® has been recognized as an orphan drug by FDA.
On November 8, 2022 US time, the oncolytic bacteria SalMet-Vec®, the core product of Sinogen Pharmaceutical, received the Orphan Drug Designation(ODD) issued by the US Food and Drug Administration(FDA) for the treatment of osteosarcoma.
Created on：2022-11-14
